166 related articles for article (PubMed ID: 32205961)
1. Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer.
Wadhwani N; Jatoi I
Indian J Surg Oncol; 2020 Mar; 11(1):12-14. PubMed ID: 32205961
[TBL] [Abstract][Full Text] [Related]
2. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
4. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.
Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C
Breast J; 2014; 20(4):381-7. PubMed ID: 24890310
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
[TBL] [Abstract][Full Text] [Related]
7. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
Buchholz TA; Katz A; Strom EA; McNeese MD; Perkins GH; Hortobagyi GN; Thames HD; Kuerer HM; Singletary SE; Sahin AA; Hunt KK; Buzdar AU; Valero V; Sneige N; Tucker SL
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):880-8. PubMed ID: 12095553
[TBL] [Abstract][Full Text] [Related]
8. Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed.
van Riet YE; Maaskant AJ; Creemers GJ; van Warmerdam LJ; Jansen FH; van de Velde CJ; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2010 Feb; 36(2):164-9. PubMed ID: 19883989
[TBL] [Abstract][Full Text] [Related]
9. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
10. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
Wu J; Kong R; Tian S; Li H; Wu K; Kong L
Chin J Cancer Res; 2019 Dec; 31(6):878-891. PubMed ID: 31949390
[TBL] [Abstract][Full Text] [Related]
11. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond.
Stravodimou A; Voutsadakis IA
Expert Rev Anticancer Ther; 2024; 24(3-4):117-135. PubMed ID: 38475990
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced breast cancer.
Sikov WM
Curr Treat Options Oncol; 2000 Aug; 1(3):228-38. PubMed ID: 12057165
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
14. Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer.
Beaver K; Williamson S; Briggs J
Eur J Oncol Nurs; 2016 Feb; 20():77-86. PubMed ID: 26078034
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
16. Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.
Oliver RT
Oncologist; 1996; 1(4):278-279. PubMed ID: 10388003
[TBL] [Abstract][Full Text] [Related]
17. Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance.
Pathak M; Deo SV; Dwivedi SN; Thakur B; Sreenivas V; Rath GK
Crit Rev Oncol Hematol; 2020 Sep; 153():103015. PubMed ID: 32563131
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
19. Role of neo-adjuvant chemotherapy in locally advanced breast cancer.
Akhtar M; Akulwar V; Kulkarni A; Bansal A
Indian J Cancer; 2015; 52(3):286-9. PubMed ID: 26905112
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy after neo-adjuvant chemotherapy in breast cancer.
Stell VH; Flippo-Morton TS; James Norton H; White RL
Breast J; 2011; 17(1):71-4. PubMed ID: 21129099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
